NCT02118337 - A Phase 1/2, Open-label Study to Evaluate the Safety and Antitumor Activity of MEDI0680 (AMP-514) in Combination With Durvalumab Versus Nivolumab Monotherapy in Participants With Select Advanced Malignancies | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

May 19, 2014

Primary Completion Date

March 17, 2020

Study Completion Date

March 17, 2020

Conditions

Select Advanced MalignanciesKidney CancerClear Cell Renal Cell Carcinoma

Interventions

BIOLOGICAL

MEDI0680

Participants will receive IV infusion of MEDI0680 0.1 or 0.5 or 2.5 or 10 or 20 mg/kg Q2W in dose-escalation phase and 20 mg/kg Q2W in dose-expansion phase.

BIOLOGICAL

Durvalumab

Participants will receive IV infusion of durvalumab 3 and 10 mg Q2W in dose-escalation phase and 750 mg Q2W in dose-expansion phase.

BIOLOGICAL

Nivolumab

Participants will receive IV infusion of nivolumab 240 mg Q2W in dose-expansion phase.

Trial Locations (27)

3165

Research Site, East Bentleigh

3199

Research Site, Frankston

10065

Research Site, New York

13009

Research Site, Marseille

21079

Research Site, Dijon

33075

Research Site, Bordeaux

33612

Research Site, Tampa

37203

Research Site, Nashville

40202

Research Site, Louisville

44195

Research Site, Cleveland

55905

Research Site, Rochester

66209

Research Site, Overland Park

73104

Research Site, Oklahoma City

75908

Research Site, Paris

90025

Research Site, Los Angeles

94805

Research Site, Villejuif

97213

Research Site, Portland

98109

Research Site, Seattle

07601

Research Site, Hackensack

17033-0850

Research Site, Hershey

M5G 2M9

Research Site, Toronto

H3T 1E2

Research Site, Montreal

1066 CX

Research Site, Amsterdam

9713 GZ

Research Site, Groningen

CB2 0QQ

Research Site, Cambridge

CF14 2TL

Research Site, Cardiff

SO16 6YD

Research Site, Southampton